Comment on "hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 study group" [2]

Richard van Merkesteyn; Dirk Jan Bakker

doi:10.1200/JCO.2005.01.1742

Comment on "hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 study group" [2]

Richard van Merkesteyn, Dirk Jan Bakker

Research output: Contribution to journal › Comment/Letter to the editor › Academic

11 Citations (Scopus)

Original language	English
Pages (from-to)	4465-4466
Journal	Journal of clinical oncology
Volume	23
Issue number	19
DOIs	https://doi.org/10.1200/JCO.2005.01.1742
Publication status	Published - 2005
Externally published	Yes

Access to Document

10.1200/JCO.2005.01.1742

Cite this

@article{7f7c9aff7f834739a7d60ac90cbad6db,

title = "Comment on {"}hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 study group{"} [2]",

author = "{van Merkesteyn}, Richard and Bakker, {Dirk Jan}",

year = "2005",

doi = "10.1200/JCO.2005.01.1742",

language = "English",

volume = "23",

pages = "4465--4466",

journal = "Journal of clinical oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "19",

}

TY - JOUR

T1 - Comment on "hyperbaric oxygen therapy for radionecrosis of the jaw

T2 - A randomized, placebo-controlled, double-blind trial from the ORN96 study group" [2]

AU - van Merkesteyn, Richard

AU - Bakker, Dirk Jan

PY - 2005

Y1 - 2005

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=22344437113&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/15994159

U2 - 10.1200/JCO.2005.01.1742

DO - 10.1200/JCO.2005.01.1742

M3 - Comment/Letter to the editor

C2 - 15994159

SN - 0732-183X

VL - 23

SP - 4465

EP - 4466

JO - Journal of clinical oncology

JF - Journal of clinical oncology

IS - 19

ER -

Comment on "hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 study group" [2]

Access to Document

Other files and links

Cite this